Ricard Mesı́a

20.3k total citations · 3 hit papers
164 papers, 7.8k citations indexed

About

Ricard Mesı́a is a scholar working on Otorhinolaryngology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Ricard Mesı́a has authored 164 papers receiving a total of 7.8k indexed citations (citations by other indexed papers that have themselves been cited), including 102 papers in Otorhinolaryngology, 95 papers in Oncology and 78 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Ricard Mesı́a's work include Head and Neck Cancer Studies (102 papers), Lung Cancer Treatments and Mutations (49 papers) and Cancer Diagnosis and Treatment (24 papers). Ricard Mesı́a is often cited by papers focused on Head and Neck Cancer Studies (102 papers), Lung Cancer Treatments and Mutations (49 papers) and Cancer Diagnosis and Treatment (24 papers). Ricard Mesı́a collaborates with scholars based in Spain, France and United States. Ricard Mesı́a's co-authors include Éva Remenár, Didier Cupissol, Ricardo Hitt, Frédéric Peyrade, Andrzej Kawecki, Sylvie Rottey, Marco Benasso, Miren Taberna, Jan B. Vermorken and Fernando Rivera and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Ricard Mesı́a

153 papers receiving 7.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer

2008 2.6k citations Ricard Mesı́a, Éva Remenár et al. profile →
Cisplatin, Fluorouracil, and Docetaxel in Unresectable Head and Neck Cancer

2007 1.2k citations Éva Remenár, Ricard Mesı́a et al. profile →
The Multidisciplinary Team (MDT) Approach and Quality of Care

2020 225 citations Miren Taberna, Ricard Mesı́a et al. profile →

Peers

Countries citing papers authored by Ricard Mesı́a

Since Specialization

Citations

This map shows the geographic impact of Ricard Mesı́a's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ricard Mesı́a with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ricard Mesı́a more than expected).

Fields of papers citing papers by Ricard Mesı́a

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ricard Mesı́a. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ricard Mesı́a. The network helps show where Ricard Mesı́a may publish in the future.

Co-authorship network of co-authors of Ricard Mesı́a

This figure shows the co-authorship network connecting the top 25 collaborators of Ricard Mesı́a. A scholar is included among the top collaborators of Ricard Mesı́a based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ricard Mesı́a. Ricard Mesı́a is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Adverse event profiles and management of cisplatin-based chemoradiotherapy in locally advanced head and neck squamous cell carcinoma: a systematic review 2025 ·Oral Oncology ·Paolo Bossi, Naomi Kiyota, Ricard Mesı́a, Ari J. Rosenberg, Rosemary Martino, (unknown), (unknown), Andreas Schröder, Sue S. Yom	1
2	Mutational Landscape of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Association with Immune Checkpoint Inhibitor Outcomes 2025 ·Clinical Cancer Research ·Patricia McCoon, Ying Wang, Zhongwu Lai, Qu Zhang, (unknown), Sophie Wildsmith, Nassim Morsli, Rajiv Raja, Nicholas Holoweckyj, Jill Walker, Melissa de los Reyes, Ricard Mesı́a, Lisa Licitra, Robert L. Ferris, Jérôme Fayette, Dan P. Zandberg, Lillian L. Siu, Robert I. Haddad	1
3	Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: 5-year follow-up from the randomized phase III KEYNOTE-048 study 2025 ·European Journal of Cancer ·Makoto Tahara, Richard Greil, Danny Rischin, Kevin J. Harrington, Barbara Burtness, Gilberto de Castro, Amanda Psyrri, Irene Braña, Prakash Neupane, Åse Bratland, Thorsten Fuereder, Brett Hughes, Ricard Mesı́a, Nuttapong Ngamphaiboon, Tamara Rordorf, Wan Zamaniah Wan Ishak, Jianxin Lin, Burak Gümüşçü, (unknown), Denis Soulières	6
4	Deciphering the impact of STAT3 activation mediated by PTPRT promoter hypermethylation as biomarker of response to paclitaxel‐plus‐cetuximab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck 2024 ·Head & Neck ·Beatriz Cirauqui, (unknown), (unknown), (unknown), José Luis Ramírez, (unknown), (unknown), Vanesa García‐Barberán, (unknown), (unknown), (unknown), (unknown), Cristina Herrero, (unknown), (unknown), Anna Esteve, Mireia Margelí Vila, Rafael Rosell, Anna Martínez‐Cardús, Ricard Mesı́a	0
5	Real‐world treatment outcomes of immune checkpoint inhibitors used off‐label in oncology: A comprehensive cancer institution experience 2024 ·Pharmacology Research & Perspectives ·(unknown), Anna Esteve, (unknown), (unknown), Ricard Mesı́a, (unknown)	2
6	Real‐world treatment outcomes of medicines used in special situations (off‐label and compassionate use) in oncology and hematology: A retrospective study from a comprehensive cancer institution 2023 ·Cancer Medicine ·(unknown), Anna Esteve, (unknown), (unknown), (unknown), Ricard Mesı́a, (unknown)	3
7	Association of PD-L1 Expression on Tumor and Immune Cells with Survival in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Assay Validation 2022 ·Cancer Research Communications ·Sophie Wildsmith, Jiabu Ye, (unknown), Giovanni Melillo, J. Armstrong, (unknown), (unknown), Fangru Lian, (unknown), Constantine Sabalos, (unknown), Jérôme Fayette, Caroline Even, Ricard Mesı́a, Lillian L. Siu, Dan P. Zandberg, Jill Walker	7
8	Clinical practice guidelines for the optimization of hemato-oncological care: the ICOPraxis 2022 ·Clinical & Translational Oncology ·(unknown), Esteve Fernández, Ricard Mesı́a, (unknown)	1
9	The potential role of imaging techniques in avoiding neck dissection during salvage surgery after head and neck carcinoma treated with bioradiotherapy 2021 ·The Journal of Laryngology & Otology ·(unknown), (unknown), Miren Taberna, Marc Oliva, Robert Montal, (unknown), Antonio Marí-Roig, J. Viñals, Alicia Lozano, M. Mañós, Ricard Mesı́a	1
10	FGFR Inhibition Overcomes Resistance to EGFR-targeted Therapy in Epithelial-like Cutaneous Carcinoma 2020 ·Clinical Cancer Research ·Adrià Bernat‐Peguera, (unknown), Laura Lorenzo-Sanz, Victoria da Silva-Diz, Mattia Bosio, Luís Palomero, R.M. Penín, (unknown), (unknown), Miren Taberna, Noelia Vilariño, Josep M. Piulats, Ricard Mesı́a, J. Viñals, Eva González‐Suárez, Salvador Capella-Gutiérrez, Alberto Villanueva, Francesc Viñals, Purificacı́on Muñoz	13
11	949P Impact of antibiotic use and derived neutrophil to lymphocyte ratio (dNLR) in patients with recurrent/metastatic head and neck squamous cell cancer (R/M HNSCC) treated with immunotherapy 2020 ·Annals of Oncology ·Nieves Plana, (unknown), (unknown), Anna Esteve, Marc Oliva, (unknown), (unknown), Noelia Vilariño, (unknown), (unknown), Ricard Mesı́a, Miren Taberna	2
12	Molecular Alterations and Buparlisib Efficacy in Patients with Squamous Cell Carcinoma of the Head and Neck: Biomarker Analysis from BERIL-1 2018 ·Clinical Cancer Research ·Denis Soulières, Lisa Licitra, Ricard Mesı́a, Éva Remenár, Shau-Hsuan Li, А. А. Карпенко, Marie Chol, Ying A. Wang, Nadia Solovieff, (unknown), Dalila Sellami, Sandrine Faivre	34
13	HPV-relatedness definitions for classifying HPV-related oropharyngeal cancer patient do impact on TNM classification and patients’ survival 2018 ·PLoS ONE ·Miren Taberna, M. Mena, Sara Tous, Miguel Ángel Pavón, Marc Oliva, Xavier León, Jacinto Garcı́a, Marta Guix, (unknown), Teresa Bonfill, (unknown), Laia Alemany, Ricard Mesı́a	12
14	KEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) 2018 ·Annals of Oncology ·Barbara Burtness, Kevin J. Harrington, Richard Greil, Denis Soulières, Makoto Tahara, Gilberto de Castro, Amanda Psyrri, (unknown), (unknown), Å. Bratland, Thorsten Fuereder, (unknown), Ricard Mesı́a, Nuttapong Ngamphaiboon, Tamara Rordorf, Wan Zamaniah Wan Ishak, Ananya Roy, J. Cheng, Fan Jin, Danny Rischin	97
15	p16, HPV, and Cetuximab: What Is the Evidence? 2017 ·The Oncologist ·James A. Bonner, Ricard Mesı́a, J. Giralt, Amanda Psyrri, Ulrich Keilholz, David I. Rosenthal, Frank Beier, Jeltje Schulten, Jan B. Vermorken	17
16	Durvalumab for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Preliminary results from a single-arm, phase 2 study 2017 ·Annals of Oncology ·Dan P. Zandberg, Alain P. Algazi, Antonio Jimeno, J. Good, Jérôme Fayette, Nathaniel Bouganim, Neal Ready, Paul Clement, (unknown), Anthony Jarkowski, J. Armstrong, Kobby Asubonteng, Giovanni Melillo, Ricard Mesı́a	24
17	Development and characterization of an isogenic cell line with a radioresistant phenotype 2012 ·Clinical & Translational Oncology ·(unknown), Marta Baro, Albert Figueras, (unknown), (unknown), Purificacı́on Muñoz, Arturo Navarro-Martín, Ricard Mesı́a, Josep Balart	21
18	Adjuvant therapy with cetuximab for locally advanced squamous cell carcinoma of the oropharynx: results from a randomized, phase II prospective trial 2012 ·Annals of Oncology ·Ricard Mesı́a, A. Rueda, Ruth Vera, Alicia Lozano, J. A. Medina, David Aguiar, F. Árias, (unknown), Joan Carles, Rafael López‐López	23
19	Management of radiation dermatitis in patients receiving cetuximab and radiotherapy for locally advanced squamous cell carcinoma of the head and neck: proposals for a revised grading system and consensus management guidelines 2011 ·Annals of Oncology ·J. Bernier, Elvio Russi, Bernhard Homey, Marco Merlano, Ricard Mesı́a, Frédéric Peyrade, Wilfried Budach	56
20	A3-05: Phase III study of vinflunine versus docetaxel in patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC) previously treated with a platinum containing regimen 2007 ·Journal of Thoracic Oncology ·Rodryg Ramlau, Jaafar Bennouna, Eng Huat Tan, Bonne Biesma, Armando Santoro, C. Boni, Helmut Klein, (unknown), Ricard Mesı́a, (unknown)	0

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact